Method and compositions for reducing cardiac dysfunctions with a selective histamine H3 receptor agonist
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 26, 2005
Grant Date -
Oct 17, 2002
app pub date -
Feb 13, 2002
filing date -
Feb 13, 2001
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The invention provides a method for reducing cardiac dysfunctions in a human. The method comprises administration to the human of an effective amount of a selective histamine H.sub.3 Receptor agonist. In one embodiment, the method comprises limiting the accumulation of intracellular sodium (Na.sub.i) by inhibiting the Na.sup.+ /H.sup.+ exchanger activity in the human having a cardiac dysfunction, or a predisposition to a cardiac dysfunction. In another embodiment the method comprises inhibiting the N-type Ca.sup.2+ channel to modulate the concentration of intracellular calcium. The invention also provides a pharmaceutical composition that includes a selective histamine H.sub.3 Receptor agonist with a pharmaceutical carrier.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully